Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 3/20 | 0.40 |
| ▸ | TGM2 | P21980 | 3/20 | 0.40 |
| ▸ | TGM1 | P22735 | 3/20 | 0.40 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992332 | 1.00 | GPR119 (0.46) | GPR119ALDH2NPC1RAB9AMMP2 | |
| SCHEMBL22789619 | 0.93 | GPR119 (0.46) | GPR119ALDH2NPC1RAB9AMMP2 | |
| SCHEMBL22770498 | 0.86 | GPR119 (0.46) | GPR119NPC1RAB9AF13A1TGM2 | |
| SCHEMBL29992909 | 0.86 | GPR119 (0.46) | GPR119NPC1RAB9AF13A1TGM2 | |
| SCHEMBL22793060 | 0.85 | GPR119 (0.52) | GPR119 | |
| SCHEMBL22770286 | 0.85 | MET (0.38) | — | |
| SCHEMBL29506183 | 0.84 | MEN1 (0.46) | GPR119NPC1RAB9AALDH1A1 | |
| SCHEMBL21856129 | 0.84 | MEN1 (0.46) | GPR119NPC1RAB9AALDH1A1 | |
| SCHEMBL22792848 | 0.83 | GPR119 (0.43) | GPR119 | |
| SCHEMBL22792391 | 0.83 | ESR2 (0.52) | GPR119NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115969853-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115721648-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20220388977-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-112174935-B | Heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-112409334-B | Heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-3984999-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | Beijing Shenogen Pharma Group Ltd. (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| CN-112409334-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112174935-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2021-01-05 | — | — | CN | disclosed |
| WO-2020249079-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | 北京盛诺基医药科技股份有限公司 | 2020-12-17 | — | — | WO | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388977-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | PTPN1, PTPN5, PTPN18 | GPR119 595/4885ALDH2 4228/4885NPC1 4146/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | GPR119 1856/4885ALDH2 3157/4885NPC1 2881/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | GPR119 1764/4885ALDH2 3237/4885NPC1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.